Cost-Effectiveness of Adding Dapagliflozin and Empagliflozin to Standard Treatment for Diabetic Kidney Disease in China
Clinical Drug Investigation · 2025
DOI: 10.1007/s40261-025-01462-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Tingting Qiu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital of Capital Medical University, No. 95, YongAn Road, Beijing, 10050, China. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Youth Beijing Scholar, Key Discipline of the National Administration of Traditional Chinese Medicine.
Abstract (Originalsprache)
BACKGROUND: Dapagliflozin and empagliflozin are emerging as promising treatment options for diabetic kidney disease (DKD). OBJECTIVE: This study sought to evaluate the cost effectiveness of incorporating dapagliflozin and empagliflozin into the standard treatment for DKD in China. METHODS: A Markov model was constructed to evaluate the cost-effectiveness of dapagliflozin and empagliflozin plus standard treatment versus standard treatment alone for DKD treatment from a healthcare perspective. Costs and utility data was obtained from published literatures within the Chinese context. The primary outcome included total cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER). GDP per capita of 2023 in China (¥89,358) was utilized as the willingness-to-pay threshold. RESULTS: Compared to standard treatment alone, add-on therapy of dapagliflozin or empagliflozin resulted in a higher total cost than those solely receiving standard treatment (+¥19,203.56 and +¥9496.92, respectively). However, both dapagliflozin and empagliflozin also yielded more life-years (+1.72 vs. +1.40) and QALYs (+1.40 vs. +0.88). The ICER per life-year and ICER per QALY was ¥11,178.52 and ¥18,192.50 for dapagliflozin and ¥6773.10 and ¥10,811.64 for empagliflozin, respectively. The incremental net monetary benefit was ¥75,120.54 and ¥68,994.90 for dapagliflozin and empagliflozin, respectively. Sensitivity analysis supported the main findings of the base-case analysis as the cost-effectiveness of dapagliflozin or empagliflozin was sustained for most plausible ranges of parameter values. CONCLUSIONS: Considering that the ICER falls below the predefined willingness-to-pay threshold, incorporating dapagliflozin and empagliflozin into standard treatment for DKD is likely to be a cost-effective strategy in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital of Capital Medical University, No. 95, YongAn Road, Beijing, 10050, China.
- Department of Public Health, Aix-Marseille University, Marseille, France.
- Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital of Capital Medical University, No. 95, YongAn Road, Beijing, 10050, China. danyan@ccmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Youth Beijing Scholar
- Key Discipline of the National Administration of Traditional Chinese Medicine
Zitieren
APA
Qiu, T., Li, P., & Yan, D. (2025). Cost-Effectiveness of Adding Dapagliflozin and Empagliflozin to Standard Treatment for Diabetic Kidney Disease in China. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01462-7
Vancouver
Qiu T, Li P, Yan D. Cost-Effectiveness of Adding Dapagliflozin and Empagliflozin to Standard Treatment for Diabetic Kidney Disease in China. Clinical Drug Investigation. 2025. doi:10.1007/s40261-025-01462-7
BibTeX
@article{Qiu2025,
author = {Qiu, Tingting and Li, Ping and Yan, Dan},
title = {Cost-Effectiveness of Adding Dapagliflozin and Empagliflozin to Standard Treatment for Diabetic Kidney Disease in China},
journal = {Clinical Drug Investigation},
year = {2025},
doi = {10.1007/s40261-025-01462-7}
}
EUVIMED